Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
Latest Information Update: 19 Jul 2022
Price :
$35 *
At a glance
- Drugs Perampanel (Primary)
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions
- Acronyms FYC02T
- Sponsors Eisai Co Ltd
- 18 Jul 2022 Results assessing safety and efficacy of perampanel for adolescent patients (aged 12-17 years) with drug-resistant, refractory epilepsy in real-world settings, published in the Epileptic Disorders.
- 06 May 2021 Status changed from active, no longer recruiting to completed.
- 10 Dec 2019 Interim results (n=89) presented at the 73rd Annual Meeting of the American Epilepsy Society